Karyopharm Therapeutics Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $35.1 million, a 17% increase from $30.0 million in the same period last year. The growth was primarily driven by a 39% rise in product revenue, which reached $29.2 million, up from $21.1 million in the prior year. This increase was attributed to a reduction in product return reserves and lower gross-to-net discounts compared to the previous year. However, license and other revenue fell by 34% to $5.9 million, largely due to the expiration of reimbursement obligations from a partner, Menarini, which had previously contributed significantly to revenue.
Operating expenses for the quarter decreased slightly to $61.8 million from $63.3 million in the prior year, reflecting a 2% reduction. Research and development expenses were $33.8 million, down from $34.6 million, while selling, general, and administrative expenses also saw a minor decline. The company reported a loss from operations of $26.8 million, an improvement from the $33.3 million loss recorded in the same quarter of 2025. The net loss for the quarter was $22.4 million, compared to a net loss of $23.5 million in the previous year.
Karyopharm's balance sheet as of March 31, 2026, showed total assets of $131.4 million, an increase from $108.4 million at the end of 2025. The company had cash and cash equivalents of $90.9 million, up from $60.5 million at the end of the previous year. This increase was bolstered by financing activities, including net proceeds of approximately $49.8 million from the issuance of common stock and warrants. The company’s accumulated deficit grew to $1.8 billion, reflecting ongoing operational losses.
Strategically, Karyopharm has been active in clinical development, with recent topline data from its Phase 3 SENTRY trial indicating promising results for its lead asset, XPOVIO, in combination with ruxolitinib for treating myelofibrosis. The company is also advancing its other clinical programs, including trials for endometrial cancer and multiple myeloma. However, Karyopharm has expressed substantial doubt regarding its ability to continue as a going concern within the next year, citing the need for additional funding to support ongoing operations and clinical trials.
Looking ahead, Karyopharm plans to address its liquidity challenges through various means, including potential equity offerings and strategic partnerships. The company aims to leverage its existing cash reserves and revenue streams to fund its operations through late 2026, while continuing to explore opportunities for additional financing to support its clinical development efforts.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics develops novel cancer therapies targeting nuclear export, primarily through its oral XPO1 inhibitors like XPOVIO (selinexor). The company focuses on hematological malignancies such as multiple myeloma, myelofibrosis, and diffuse large B-cell lymphoma, as well as solid tumors like endometrial cancer. Its business model combines drug discovery, clinical development, and global commercialization, leveraging strategic partnerships to address high unmet medical needs with first-in-class, mechanism-based treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.